8-K: DiaMedica Therapeutics Secures $11.8 Million in Private Placement to Advance Clinical Programs

DiaMedica Therapeutics has announced an $11.8 million private placement to fund its clinical trials, including expansion into preeclampsia.

Summary

• DiaMedica Therapeutics Inc. has entered into securities purchase agreements for a private placement.
• The company will issue 4,720,000 common shares at $2.50 per share.
• The private placement is expected to close around June 28, 2024, pending customary conditions.
• DiaMedica anticipates gross proceeds of $11.8 million from this placement.
• The net proceeds will be used to expand clinical trials into preeclampsia and for general corporate purposes.
• A registration rights agreement is in place to register the resale of these shares.
• The company expects the financing to extend its cash runway into the third quarter of 2026.

Sentiment

Score: 7

Explanation: The document is generally positive, highlighting a successful capital raise and expansion into a new clinical area. However, there are some risks and potential negatives associated with the private placement, such as dilution and potential liquidated damages.

Positives

• The private placement provides significant funding for clinical trials.
• The expansion into preeclampsia addresses a significant unmet medical need.
• The extended cash runway provides financial stability for the company.
• The registration rights agreement provides liquidity for investors.

Negatives

• The private placement dilutes existing shareholders' equity.
• The company is subject to potential liquidated damages if it fails to meet registration deadlines.

Risks

• The closing of the private placement is subject to customary closing conditions.
• The company may face challenges in meeting the deadlines for filing and effectiveness of the resale registration statement.
• There is a risk of potential liquidated damages if the company fails to meet the registration deadlines.
• Clinical trials are subject to inherent risks and may not yield favorable results.
• The company's cash runway is only extended to the third quarter of 2026, requiring further funding in the future.

Future Outlook

The company plans to use the net proceeds to expand its clinical trials into preeclampsia and continue its pivotal Phase 2/3 ReMEDy2 trial for acute ischemic stroke, with the financing expected to extend the cash runway into the third quarter of 2026.

Management Comments

• The company expects to use the net proceeds from the private placement to continue its clinical and product development activities for DM199.
• The financing is expected to extend DiaMedica's cash runway into the third quarter of 2026.

Industry Context

The expansion into preeclampsia aligns with a growing focus on addressing unmet medical needs in women's health. The company's focus on ischemic diseases is also relevant given the prevalence of conditions like stroke.

Comparison to Industry Standards

• Private placements are a common method for biotech companies to raise capital, especially for funding clinical trials.
• The size of the raise, $11.8 million, is typical for a company of DiaMedica's size and stage.
• The use of proceeds for clinical trials and working capital is standard practice in the biotech industry.
• The inclusion of a registration rights agreement is a common practice to provide liquidity to investors in private placements.

Related Party Transactions

• DiaMedica has received binding commitments for participation in the private placement from certain non-management, related parties, in the aggregate amount of $6.0 million or 2,400,000 common shares.
• The private placement constitutes a related party transaction under Canadian regulations but is exempt from certain requirements due to its size.

Stakeholder Impact

• Shareholders will experience dilution due to the issuance of new shares.
• The company's employees will benefit from the continued funding of clinical programs.
• Patients with acute ischemic stroke and preeclampsia may benefit from the development of new treatments.
• Investors in the private placement will have the opportunity to profit from the company's future success.

Next Steps

• The company will close the private placement on or about June 28, 2024.
• The company will file a registration statement with the SEC to register the resale of the common shares.
• The company will use the net proceeds to expand its clinical trials into preeclampsia and continue its ReMEDy2 trial.
• The company will continue to develop DM199 for acute ischemic stroke and preeclampsia.

Key Dates

Keywords

private placement, clinical trials, preeclampsia, DM199, rinvecalinase alfa, acute ischemic stroke, registration rights, capital raise, biopharmaceutical, financing